Parameters | Training cohort (n = 225) | Internal validation cohort (n = 98) | external validation cohort (n = 69) | ||||||
---|---|---|---|---|---|---|---|---|---|
LNM group (n = 75) | Non-LNM group (n = 150) | p | LNM group (n = 33) | Non-LNM group (n = 65) | p | LNM group (n = 20) | Non-LNM group (n = 49) | p | |
Age (years) | 0.920 | 0.72 | 0.140 | ||||||
≥ 50 | 48 | 94 | 17 | 36 | 12 | 38 | |||
< 50 | 27 | 56 | 16 | 29 | 8 | 11 | |||
Menstrual state | 0.700 | 0.73 | 0.770 | ||||||
Menopause | 49 | 48 | 19 | 35 | 13 | 37 | |||
Premenopausal | 26 | 102 | 14 | 30 | 7 | 12 | |||
SCC-Ag (ng/L) | < 0.001 | 0.02 | 0.020 | ||||||
≥ 1.5 | 48 | 47 | 18 | 20 | 13 | 17 | |||
< 1.5 | 27 | 103 | 15 | 45 | 7 | 32 | |||
Pathological type | 0.460 | 0.22 | 0.880 | ||||||
Squamous cell carcinoma | 68 | 131 | 30 | 53 | 18 | 44 | |||
Adenocarcinoma | 7 | 19 | 3 | 12 | 2 | 5 | |||
Histologic grade | 0.510 | 0.16 | 0.400 | ||||||
High/middle | 40 | 87 | 26 | 58 | 14 | 39 | |||
Low | 35 | 63 | 7 | 7 | 6 | 10 | |||
LNmax short diameter (mm) | < 0.001 | 0.008 | 0.004 | ||||||
≥ 10 | 18 | 5 | 23 | 6 | 8 | 5 | |||
< 10 | 57 | 145 | 10 | 59 | 12 | 44 | |||
Maximum tumour diameter (mm) | < 0.001 | 0.030 | 0.052 | ||||||
≥ 40 | 38 | 26 | 14 | 14 | 7 | 7 | |||
< 40 | 37 | 124 | 19 | 51 | 13 | 42 | |||
Tumour volume (cm3) | < 0.001 | 0.005 | 0.020 | ||||||
≥ 15 | 31 | 35 | 13 | 20 | 10 | 11 | |||
< 15 | 44 | 115 | 20 | 45 | 10 | 38 |